<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248127</url>
  </required_header>
  <id_info>
    <org_study_id>1492622</org_study_id>
    <nct_id>NCT04248127</nct_id>
  </id_info>
  <brief_title>The Influence of Honey-flavored Yogurt on Low-grade Inflammation and Gut Health in Middle to Older Aged Women.</brief_title>
  <official_title>The Influence of Honey-flavored Yogurt on Low-grade Inflammation and Gut Health in Middle to Older Aged Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, crossover dietary intervention trial will test the effects of 4&#xD;
      weeks of daily honey-flavored yogurt intake on markers of inflammation (Th17 cytokines) and&#xD;
      oxidative stress (NOX2, UA, RSNO) and associative changes with microbial derived metabolites&#xD;
      (SCFAs, BAs, ellagitannins), metabolism and the fecal microbiome. The above suite of selected&#xD;
      markers will capture diet-induced systemic changes in inflammation and oxidative stress,&#xD;
      while assessing associated microbial changes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Those qualified for enrollment will be randomized into a double-blind crossover study to&#xD;
      consume 2 morning servings of a 0.6 cup (150g) of plain yogurt with : A) cane sugar added in&#xD;
      an isocaloric level as the honey or, B) 1 tbsp of phenolic-rich honey for 4 weeks. A&#xD;
      one-month washout between periods will be used. The participants will be instructed to&#xD;
      consume one yogurt in replacement of or as part of breakfast, and as a late morning snack.&#xD;
      They will also be instructed to not add any additional items to the yogurt. Therefore, each&#xD;
      study participant will consume 2 tbsp. of honey a day for four weeks, which is a realistic&#xD;
      amount typically consumed by honey users.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized single-blind 2-arm crossover trial. Each arm will be 4 weeks in length, with a 4 week washout between arms.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The honey intervention or isocaloric amounts of sugar will be provided in yogurt. The study participant will not be told what sweetener they will be receiving.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of CD4+ T Helper (TH)17 cytokines</measure>
    <time_frame>4 weeks</time_frame>
    <description>Cytokines included in the panel are: Il-1b, IL-4, IL-6, IL-10, IL-17a, IL-21, IL-22, IL-23, IL-31, IL-33, IFN-gamma, TNF-alpha, IL-17f.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Secondary bile acids</measure>
    <time_frame>4 weeks</time_frame>
    <description>plasma microbial metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Short chain fatty acids</measure>
    <time_frame>4 weeks</time_frame>
    <description>Fecal microbial metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of urolithins and other ellagitannin-derived metabolites</measure>
    <time_frame>4 weeks</time_frame>
    <description>microbial metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of soluble NADPH oxidase (NOX2)</measure>
    <time_frame>4 weeks</time_frame>
    <description>plasma marker oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of uric acid</measure>
    <time_frame>4 weeks</time_frame>
    <description>plasma marker oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of total Nitrate/Nitrite and Nitric Oxide related metabolites (RSNO)</measure>
    <time_frame>4 weeks</time_frame>
    <description>dietary nitrate and NO metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of untargeted metabolomics</measure>
    <time_frame>4 weeks</time_frame>
    <description>metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of microbial populations</measure>
    <time_frame>4 weeks</time_frame>
    <description>stool bacterial population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Honey sweetened yogurt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tbsp. of honey in 0.6 cup (150g) of plain yogurt. The participants will be asked to consume 2 morning servings of the yogurt for a total of 2 tbsp. of the assigned honey per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar sweetened yogurt</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar will be added to 0.6 cup (150g) of plain yogurt in an isocaloric amount compared to the honey. The participants will be asked to consume 2 morning servings of the yogurt per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Honey sweetened yogurt</intervention_name>
    <description>2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions</description>
    <arm_group_label>Honey sweetened yogurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar sweetened yogurt</intervention_name>
    <description>sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions</description>
    <arm_group_label>Sugar sweetened yogurt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal female: 45-65 years&#xD;
&#xD;
          -  Women: lack of menses for at least two years.&#xD;
&#xD;
          -  Subject is willing and able to comply with the study protocols.&#xD;
&#xD;
          -  Subject is willing to participate in all study procedures&#xD;
&#xD;
          -  BMI 25.0 - 30.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI ≥ 31 kg/m2&#xD;
&#xD;
          -  Food allergies&#xD;
&#xD;
          -  Self-reported use of daily anticoagulation agents including aspirin, NSAIDs&#xD;
&#xD;
          -  Vegan, Vegetarians, food faddists or those consuming a non-traditional diet&#xD;
&#xD;
          -  Use of concentrated food supplements/powders and extracts&#xD;
&#xD;
          -  Fruit consumption &gt; 2 cups/day&#xD;
&#xD;
          -  Vegetable consumption &gt;3 cups/day&#xD;
&#xD;
          -  Self-reported restriction of physical activity due to a chronic health condition&#xD;
&#xD;
          -  Self-reported chronic/routine high intensity exercise&#xD;
&#xD;
          -  Self-reported diabetes&#xD;
&#xD;
          -  Blood pressure ≥ 140/90 mm Hg&#xD;
&#xD;
          -  Self-reported renal or liver disease&#xD;
&#xD;
          -  Self-reported heart disease, which includes cardiovascular events and stroke&#xD;
&#xD;
          -  Abnormal Metabolic or CBC panels (laboratory values outside the reference range) if&#xD;
             determined to be clinically significant by the study physician.&#xD;
&#xD;
          -  Self-reported cancer within past 5 years&#xD;
&#xD;
          -  Self-reported malabsorption&#xD;
&#xD;
          -  Currently taking prescription drugs or supplements.&#xD;
&#xD;
          -  Supplement use other than a general formula of vitamins and minerals that meet the RDA&#xD;
&#xD;
          -  Not willing to stop any supplement use, including herbal, plant or botanical, fish&#xD;
             oil, oil supplements a month prior to study enrollment.&#xD;
&#xD;
          -  Indications of substance or alcohol abuse within the last 3 years&#xD;
&#xD;
          -  Cannabis use&#xD;
&#xD;
          -  Screening LDL ≥ 190 mg/dl for those who have 0-1 major risk factors apart from LDL&#xD;
             cholesterol (i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL]. (using NCEP calculator&#xD;
             http://cvdrisk.nhlbi.nih.gov/calculator.asp)&#xD;
&#xD;
          -  Screening LDL ≥ 160 mg/dl for those who have 2 major risk factors apart from LDL&#xD;
             cholesterol [i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL]. (using NCEP calculator&#xD;
             http://cvdrisk.nhlbi.nih.gov/calculator.asp);&#xD;
&#xD;
          -  Screening LDL ≥ 130 mg/dl for those who have 2 major risk factors apart from LDL&#xD;
             cholesterol [i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL], and a Framingham 10-year Risk Score 10-20% (using NCEP&#xD;
             calculator http://cvdrisk.nhlbi.nih.gov/calculator.asp).&#xD;
&#xD;
          -  Current enrollee in a clinical research study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl L Keen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis; Department of Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert R Holt, PhD</last_name>
    <phone>530-752-4950</phone>
    <email>rrholt@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Davis; Department of Nutrition</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phenolic</keyword>
  <keyword>Honey</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Yogurt</keyword>
  <keyword>Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT04248127/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

